Mavacamten Approved in Canada Published on November 11, 2022 by hcmbeat Bristol Myers Squibb’s first in class drug mavacamten (brand name Camzyos) has been approved by Health Canada for the treatment of obstructive hypertrophic cardiomyopathy. Share this:Click to share on Facebook (Opens in new window)Click to share on Twitter (Opens in new window)Click to email a link to a friend (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Pinterest (Opens in new window)MoreClick to print (Opens in new window)Like this:Like Loading...
HCM Beat 